← Eichor
Condition: Transfusion Dependent Thalassemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Transfusion Dependent Thalassemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]
EARLY_Phase 1 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05762510Β-Thalassemia Treatment with KL003 Cell Injection
Phase 1/Phase 2 · 2 location(s) · Kanglin Biotechnology (Hangzhou) Co., Ltd. · NCT06280378Long-term Follow-up Study of BRL-101 for TDT
Phase N/A · 7 location(s) · Bioray Laboratories · NCT06298630A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Particip
Phase 1 · 1 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05757245Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent Beta-thalassemia
NA · 1 location(s) · Shanghai BDgene Co., Ltd. · NCT05773729A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle East
Phase N/A · 2 location(s) · Bristol-Myers Squibb · NCT07215975A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharma
Phase 2 · 36 location(s) · Bristol-Myers Squibb · NCT05664737A Phase 1 Study of Gene-modified Autologous Hematopoietic Stem Cell (BD211) Treating β-thalassemia Major
Phase 1 · 3 location(s) · Shanghai BDgene Co., Ltd. · NCT06465550Growth and Development-related Outcomes in Children With Transfusion-dependent Beta-thalassemia After Gene Therapy
Phase N/A · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT05991336A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemia
Phase 1 · 2 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06772766the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
EARLY_Phase 1 · 1 location(s) · Shenzhen Hemogen · NCT05864170Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia
Phase 2 · 1 location(s) · National Institute of Blood and Marrow Transplant (NIBMT), P · NCT06490627Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in Β-thalassaemia Patients.
Phase 1 · 3 location(s) · Shenzhen Hemogen · NCT06655662Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
NA · 1 location(s) · Shanghai BDgene Co., Ltd. · NCT05776173A Study of Safety and Efficiency of AND017 in Patients With β-thalassemia
Phase 2 · 5 location(s) · Kind Pharmaceuticals LLC · NCT06302491Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients
NA · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT06219239Gene-Modified Stem Cell Therapy for Subjects With Transfusion-dependent Beta-thalassemia
Phase 2 · 2 location(s) · Fondazione Telethon · NCT07680803Evaluation of Physiological and Psychological Factors Involved in Exercise Intolerance in Patients With β-TTD
NA · 1 location(s) · Centre Hospitalier Metropole Savoie · NCT07207577T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias
Phase 1/Phase 2 · 1 location(s) · Paul Szabolcs · NCT03653338Evaluating the Clinical Efficacy and Safety of Luspatercept Combined With Thalidomide in the Treatment of β-TDT Patients
Phase 2 · 8 location(s) · Rongrong Liu · NCT07338344Long-term Follow-up Study of BHC001 for TDT
Phase N/A · 2 location(s) · Bioray Laboratories · NCT06314529A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes
Phase 2 · 1 location(s) · Pharmacosmos A/S · NCT05693909Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia an
Phase 3 · 6 location(s) · Vertex Pharmaceuticals Incorporated · NCT05477563Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Phase 2 · 1 location(s) · Paul Szabolcs · NCT01962415Hematopoietic Stem Cell BCL11A Enhancer Gene Editing for Severe β-Hemoglobinopathies
Phase 1 · 1 location(s) · Daniel Bauer · NCT06647979Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploid
Phase 2 · 5 location(s) · Rongrong Liu · NCT06657391ALS20-101 Lentiviral Gene Therapy for Beta Thalassemia
Phase 1/Phase 2 · 1 location(s) · Children's Hospital of Philadelphia · NCT06364774the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia
EARLY_Phase 1 · 1 location(s) · Shenzhen Hemogen · NCT05851105
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.